Wall Street Zen Downgrades Actuate Therapeutics to Sell

Analysts cite concerns about the company's future performance and growth prospects.

Published on Mar. 7, 2026

Got story updates? Submit your updates here. ›

Investment firm Wall Street Zen has downgraded shares of Actuate Therapeutics (NASDAQ:ACTU) from a "hold" rating to a "sell" rating, citing worries about the company's outlook. This comes after other analysts have issued mixed ratings on the stock, with some maintaining a "buy" recommendation while one other firm has also assigned a "sell" rating.

Why it matters

Actuate Therapeutics is a clinical-stage oncology company focused on developing targeted therapies for difficult-to-treat cancers. The downgrade from Wall Street Zen could signal broader concerns about the company's ability to successfully advance its pipeline and translate its research into commercially viable products.

The details

In its report, Wall Street Zen cited a number of factors contributing to the downgrade, including Actuate's recent stock performance and valuation. The company's shares have fallen over 10% so far this year and are trading well below their 52-week high. Wall Street Zen also noted uncertainty around the progress of Actuate's lead drug candidate, atuveciclib, which is in Phase 1 clinical trials for acute myeloid leukemia and solid tumors.

  • Actuate Therapeutics stock opened at $2.86 on Friday, March 7, 2026.
  • The company's shares have a 52-week low of $2.73 and a 52-week high of $11.99.

The players

Wall Street Zen

An investment research firm that provides analysis and ratings on publicly traded companies.

Actuate Therapeutics

A clinical-stage oncology company focused on developing targeted therapies for difficult-to-treat cancers.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The downgrade from Wall Street Zen underscores the challenges Actuate Therapeutics faces as it works to advance its pipeline and establish itself as a leader in the competitive oncology drug development space. Investors will be closely watching the company's progress with atuveciclib and any other pipeline updates in the coming months.